A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

This Phase I intervention trial (n=80) will assess the safety, tolerability, and pharmacokinetics of psilocybin (MLS101 ) in healthy participants.

MLS101 is a low-dose psilocybin being developed for neurological and psychiatric conditions. The trial aims to evaluate the safety, distribution, and clearance of MLS101, as well as its psychedelic effects in healthy adults. Microdoses of psilocybin, which are doses absent of profound sensory and cognitive effects, will be administered to participants in a controlled manner.

The study is designed as a randomized, double-blind, placebo-controlled, single ascending, and multiple-dose study. In the first part, 24 participants will be enrolled in three sequential dose cohorts and receive a single dose of MLS101 or a placebo. The study will also explore additional doses if necessary.

The second part of the study will involve multiple doses, and the doses and administration regimens will depend on the results from the first part.

The trial, conducted by MycoMedica Life Sciences PBC, commenced in March 2024 and is estimated to be completed by October 2024.

Topic Healthy Subjects Safety Neurocognitive Disorders
Compound Psilocybin Placebo
Country Australia
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.